Real‐world data show high efficacy of <scp>IL23</scp> inhibitors guselkumab and risankizumab in psoriatic arthritis and difficult‐to‐treat areas

Vaiopoulos, Aristeidis G.; Dalamaga, Maria; Katsimbri, Pelagia; Koumourtzis, Marios; Lampadaki, Kyriaki; Theodoropoulos, Konstantinos; Theotokoglou, Sofia; Kanelleas, Antonios; Syrmali, Anna; Filippopoulou, Alexandra; Zoupidou, Konstantina; Katoulis, Alexander; Papadavid, Evangelia

doi:10.1111/ijd.16849

Cited by 4 publications

(1 citation statement)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The drug retention rate (DRR) is a widely accepted metric to study the effectiveness in cohorts of patients from clinical practice by the assessment of the persistence of therapy over time. In the context of PsA, few studies investigated the effectiveness of guselkumab in ''real-life'' studies [23][24][25].…”

Section: Introductionmentioning

confidence: 99%

The Evaluation of Effectiveness and Safety of Guselkumab in Patients with Psoriatic Arthritis in a Prospective Multicentre “Real-Life” Cohort Study

Ruscitti,

Cataldi,

Gentile

et al. 2024

Rheumatol Ther

View full text Add to dashboard Cite

Introduction Guselkumab is an interleukin-23 (IL-23) inhibitor licensed for the treatment of psoriatic arthritis (PsA). This study aimed to evaluate the 6-month effectiveness of guselkumab in patients with PsA in a “real-life” multicentre patient cohort. We also estimated the drug retention rate (DRR) of gusulkumab, also assessing the impact of comorbidities and patient clinical characteristics, in a collective 18-month prospective follow-up. Methods Between December 2021 and September 2023, consecutive patients with PsA were evaluated if treated at least for 6 months with guselkumab in a prospective multicentre study to evaluate the effectiveness of the drug by means of disease activity index for psoriatic arthritis (DAPSA) and cumulative DRR. Results A total of 111 patients with PsA were evaluated and treated with guselkumab (age 56.8 ± 9.9, male sex 20.7%). These patients were mainly characterised by active and long-standing PsA with median disease duration of 6.0 (7.0) years (55.9% disease duration ≥ 5 years), 55.0% showed comorbidities, 78.4% of patients were previously treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs), and 60.4% concomitantly with conventional synthetic DMARDs (csDMARDs). After 6 months, a significant reduction of DAPSA was observed ( β − 15.47, p = 0.001, 95% CI − 23.15 to − 9.79) with 39.6% of patients achieving a DAPSA ≤ 14. At the end of cumulative follow-up, 71.2% of patients were still treated with guselkumab whereas 24.3% discontinued the drug because of inefficacy. An 18-month DRR of guselkumab of 66.7% was estimated with a mean time of administration of 9.8 ± 4.1 months. The results of the DRR were stratified according to patient clinical characteristics. The DRR of guselkumab appeared to be not influenced by long disease duration, comorbidities, obesity, concomitant csDMARDs, and previous bDMARDs. Conclusion The “real-life” 6-month effectiveness of guselkumab was shown in patients with PsA, mainly characterised by active long-standing disease, previously treated with bDMARDs, and with comorbidities. Furthermore, a good DRR of guselkumab was estimated in the cumulative 18 months of follow-up and appeared to be not influenced by long disease duration, comorbidities, obesity, and previous bDMARDs.

show abstract

Section: Introductionmentioning

confidence: 99%